156 related articles for article (PubMed ID: 34349468)
1. Just not cosmesis! Role of low-density lipoprotein apheresis in familial hypercholesterolemia: Experience at a newly developed tertiary care institution in Northern India.
Kaur D; Negi G; Walia R; Malhotra S; Bhatia R; Meinia SK; Mandal S; Jain A
Asian J Transfus Sci; 2021; 15(1):104-108. PubMed ID: 34349468
[TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein apheresis in a pediatric patient of familial hypercholesterolemia: Primi experientia from a tertiary care center in North India.
Dogra K; Goyal A; Khadgawat R; Gupta Y; Rout D; Fulzele PP; Chaurasia R; Coshic P; Chatterjee K
Asian J Transfus Sci; 2017; 11(1):58-61. PubMed ID: 28316443
[TBL] [Abstract][Full Text] [Related]
3. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
Aljenedil S; Ruel I; Watters K; Genest J
J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01).
Torres E; Goicoechea M; Hernández A; Rodríguez Ferrero ML; García A; Macías N; Anaya F
J Clin Apher; 2020 Jan; 35(1):9-17. PubMed ID: 31663632
[TBL] [Abstract][Full Text] [Related]
6. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
7. Familial Hypercholesterolemia and Lipoprotein Apheresis.
Makino H; Koezuka R; Tamanaha T; Ogura M; Matsuki K; Hosoda K; Harada-Shiba M
J Atheroscler Thromb; 2019 Aug; 26(8):679-687. PubMed ID: 31231083
[TBL] [Abstract][Full Text] [Related]
8. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
Lee WP; Datta BN; Ong BB; Rees A; Halcox J
Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
[TBL] [Abstract][Full Text] [Related]
9. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).
Matsuzaki M; Hiramori K; Imaizumi T; Kitabatake A; Hishida H; Nomura M; Fujii T; Sakuma I; Fukami K; Honda T; Ogawa H; Yamagishi M
J Am Coll Cardiol; 2002 Jul; 40(2):220-7. PubMed ID: 12106923
[TBL] [Abstract][Full Text] [Related]
10. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
[TBL] [Abstract][Full Text] [Related]
11. Autosomal recessive hypercholesterolemia: Case report.
Petrulioniene Z; Gargalskaite U; Mikstiene V; Norvilas R; Skiauteryte E; Utkus A
J Clin Lipidol; 2019; 13(6):887-893. PubMed ID: 31734096
[TBL] [Abstract][Full Text] [Related]
12. Treatment of homozygous familial hypercholesterolemia with low density lipoprotein apheresis: a 4 year follow-up study.
Fadul JE; Vessby B; Wikström B; Danielson BG
Artif Organs; 1997 May; 21(5):364-8. PubMed ID: 9129767
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.
Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Aukrust P; Retterstøl K; Ose L; Halvorsen B; Holven KB
J Clin Lipidol; 2013; 7(2):109-16. PubMed ID: 23415429
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.
Richter WO; Donner MG; Höfling B; Schwandt P
Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236
[TBL] [Abstract][Full Text] [Related]
15. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
[TBL] [Abstract][Full Text] [Related]
16. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.
Zenti MG; Stefanutti C; Sanga V; Altomari A; Fabris A; Dauriz M; Bonora E
J Clin Apher; 2018 Aug; 33(4):546-550. PubMed ID: 29638018
[TBL] [Abstract][Full Text] [Related]
17. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.
van Wijk DF; Sjouke B; Figueroa A; Emami H; van der Valk FM; MacNabb MH; Hemphill LC; Schulte DM; Koopman MG; Lobatto ME; Verberne HJ; Fayad ZA; Kastelein JJ; Mulder WJ; Hovingh GK; Tawakol A; Stroes ES
J Am Coll Cardiol; 2014 Oct; 64(14):1418-26. PubMed ID: 25277610
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia.
Makino H; Harada-Shiba M
Ther Apher Dial; 2003 Aug; 7(4):397-401. PubMed ID: 12887721
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
Bambauer R; Olbricht CJ; Schoeppe E
Ther Apher; 1997 Aug; 1(3):242-8. PubMed ID: 10225746
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
